



TO THE EDITOR:

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

Xinyi Xia,^{1,3,*} Kening Li,^{4,5,*} Lingxiang Wu,^{4,5,*} Zhihua Wang,^{2,3,6,*} Mengyan Zhu,^{4,5} Bin Huang,^{4,5} Jie Li,^{4,5} Ziyu Wang,^{4,5} Wei Wu,^{4,5} Min Wu,^{4,5} Wanlin Li,^{4,5} Lu Li,^{4,5} Yun Cai,^{4,5} Bakwatanisa Bosco,^{4,5} Aifang Zhong,^{2,7} Xiong Liu,^{3,8} Tangfeng Lv,^{3,9,10} Zhenhua Gan,^{3,9} Guang Chen,^{10,11} Yunhu Pan,^{10,12} Caidong Liu,¹³ Kai Zhang,¹³ Xiaoli Xu,^{3,9,10} Changjun Wang,^{3,8} and Qianghu Wang^{4,5,14}

¹COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; ²Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, China; ³Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, China; ⁴Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China; ⁵Department of Bioinformatics, Nanjing Medical University, Nanjing, China; ⁶Department of Laboratory Medicine & Blood Transfusion, the 907th Hospital, Nanping, China; ⁷Medical Technical Support Division, the 904th Hospital, Changzhou, China; ⁸Center for Disease Control and Prevention of PLA, Beijing, China; ⁹Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; ¹⁰Department of Infectious Disease, Wuhan Huoshenshan Hospital, Wuhan, China; ¹¹Department of Respiratory Medicine, the 907th Hospital, Nanping, China; ¹²Intensive Care Unit, the 907th Hospital, Nanping, China; ¹³General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; and ¹⁴Biomedical Big Data Center, Nanjing Medical University, Nanjing, China

COVID-19 has spread to >210 countries and territories worldwide.¹⁻⁴ Although some agents are under investigation, there are no targeted drugs that could effectively eliminate or treat the novel virus.^{5,6} Treatments for patients with COVID-19 are urgently needed, especially for severe or critical cases. COVID-19 convalescent plasma (CCP) therapy involves the administration of plasma from patients who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infections.^{7,8} Although several case series and an open-label trial regarding CCP for patients with COVID-19 were previously reported,⁹⁻¹² the effectiveness and safety of CCP have still not been comprehensively evaluated in large retrospective cohorts or randomized blinded trials. Herein, we present the results of 1568 patients with severe or critical COVID-19, including 1430 patients who received standard treatment only and 138 patients who also received ABO-compatible CCP, in Wuhan Huoshenshan Hospital (China), admitted from 4 February 2020 to 30 March 2020.

The clinical characteristics of patients were compared between the CCP group and the standard treatment group (Table 1). According to the clinical status and body weight of each recipient, 200 to 1200 mL of CCP was transfused (supplemental Methods, available on the *Blood* Web site; supplemental Figure 1). A 6-category scale score (SCSS) was used to evaluate the clinical status. Despite the higher severity level, only 3 patients (2.2%) died in the CCP group up to April 20, reducing ~50% of the mortality rate compared with that in the standard treatment group (4.1%). Notably, for the 126 non-ICU patients before CCP therapy, 3 patients (2.4%) were admitted to the ICU, compared with 72 (5.1%) of 1403 ICU admissions in the standard treatment group.

We analyzed the dynamic changes in the SARS-CoV-2 viral load of nasopharyngeal swabs, anti-SARS-CoV-2 antibody levels, and various types of laboratory and radiologic parameters before and after CCP therapy. Within 14 days following CCP therapy, 20 (80%) of the 25 patients who were positive for SARS-CoV-2 became virus free (Figure 1A). The levels of the spike (S)- and

receptor binding domain (RBD)-specific immunoglobulin G (IgG) increased within 3 days, which then slightly decreased within 3 to 7 days after CCP therapy. However, nucleoprotein (N)-specific antibody levels did not increase after CCP therapy (Figure 1B). According to a previous study, S- and RBD-specific IgGs play an important role in neutralizing viruses,¹³ indicating that the immediate increase in S- and RBD-specific IgG was one of the reasons for CCP efficacy. Moreover, antibody levels in the CCP units positively correlated with the antibody changes in recipients ($r = 0.4$; $P = .02$) (supplemental Figure 2A). In addition, the percentage of lymphocytes significantly increased within 3 days ($P = .0009$) and was maintained at a relatively high level within 21 days after CCP therapy, whereas the neutrophil percentage significantly decreased. The concentration of C-reactive protein decreased after CCP therapy (Figure 1C-F), indicating the anti-inflammatory effect of CCP.¹⁴ Moreover, 77.9% of cases represented lung lesion absorption within 14 days after CCP therapy (Figure 1G).

To investigate the safety of CCP, cardiac, liver, and renal functions were assessed by analyzing the results of routine blood and biochemistry examinations (supplemental Table 1). None of these indexes showed significant differences before and after CCP therapy, except for the decrease in total bilirubin levels. In addition, levels of cytokines such as tumor necrosis factor- α , interleukin-10, and interleukin-6 were compared before and after CCP therapy. The results showed that all of these cytokines remained at the original level. In addition, 3 patients had minor allergic reactions (pruritus or erythema) during the transfusion, but no severe transfusion reactions such as transfusion-associated circulatory overload, transfusion-related acute lung injury, or severe allergic reactions were observed. Along with results of recent reports,¹⁵ the low rate of serious adverse events is reassuring.

We classified patients treated with CCP as responders, partial responders, and nonresponders according to the SCSS (supplemental Methods) and investigated the differences in various

Table 1. Comparison of clinical characteristics between the CCP and the standard treatment group of patients with severe/critical COVID-19

Characteristic	Total (N = 1568)	CCP (n = 138)	Standard treatment (n = 1430)	P
Age, median (IQR), y	63 (54-71)	65 (57-73)	63 (53-71)	.008
Sex, no. (%)				.3
Female	771 (49.2)	61 (44.2)	710 (49.7)	—
Male	797 (50.8)	77 (55.8)	720 (50.3)	—
Comorbidity, no. (%)				
Hypertension	565 (36.0)	53 (38.4)	508 (35.5)	.5
Diabetes	252 (16.1)	31 (22.5)	218 (15.2)	.04
Cardiovascular disease	239 (15.2)	27 (19.6)	210 (14.7)	.1
Cerebrovascular disease	89 (5.7)	12 (8.7)	75 (5.2)	.1
Malignancy	61 (3.9)	4 (2.9)	53 (3.7)	.8
Chronic obstructive pulmonary disease	105 (6.7)	12 (8.7)	91 (6.4)	.3
Chronic renal disease	37 (2.4)	4 (2.8)	33 (2.3)	.6
Chronic liver disease	44 (2.8)	4 (2.9)	39 (2.7)	.8
Immunodeficiency	6 (0.4)	2 (1.4)	4 (0.28)	.09
Symptoms, no. (%)				
Fatigue	625 (39.9)	57 (41.3)	564 (39.4)	.7
Fever	1080 (68.9)	93 (67.4)	984 (68.8)	.8
Cough	952 (60.7)	83 (60.1)	863 (60.3)	1
Shortness of breath	181 (11.5)	28 (20.3)	150 (10.5)	.001
Chest congestion	200 (12.8)	24 (17.4)	175 (12.2)	.1
Nausea or vomiting	16 (1.0)	2 (1.4)	13 (0.9)	.4
Diarrhea	43 (2.7)	4 (2.9)	39 (2.7)	.8
Highest temperature, median (IQR), °C	37.1 (36.9-37.4)	37.2 (37.0-37.4)	37.1 (36.9-37.3)	.008
Days from symptoms onset to admission, median (IQR)	25 (14-35)	35 (18-40)	25 (14-35)	<.001
Days from admission to discharge, median (IQR)	14 (8-22)	22 (16-30)	14 (8-21)	<.001
Days from symptoms onset to CCP therapy, median (IQR)	—	45 (39-54)	—	—
Degree of severity, no. (%)				.009
Severe	1420 (90.6)	116 (84.1)	1304 (91.2)	
Critical	148 (9.4)	22 (15.9)	126 (8.8)	
Highest SCSS during hospitalization, no. (%)				.04
2: Hospitalized, not requiring oxygen	730 (46.6)	55 (39.9)	675 (50.4)	—
3: Low-flow oxygen therapy	519 (33.1)	50 (36.2)	469 (35.0)	—
4: High-flow oxygen therapy or noninvasive mechanical ventilation	252 (16.1)	28 (20.3)	224 (16.7)	—
5: ECMO or invasive mechanical ventilation	5 (0.3)	2 (1.4)	3 (0.2)	—
ICU admission, no. (%)	75 (4.9)	3 (2.4)	72 (5.1)	.2
Clinical outcomes, no. (%)				<.001
Discharge from hospital	1487 (94.8)	121 (87.7)	1366 (95.5)	—
Death	62 (4.0)	3 (2.2)	59 (4.1)	—
Hospitalization	19 (1.2)	14 (10.1)	5 (0.3)	—

P values marked in bold indicate the significant differences between CCP and standard treatment groups. ECMO, extracorporeal membrane oxygenation; IQR, interquartile range.

laboratory parameters between these groups before CCP therapy (supplemental Table 2). The lymphocyte percentage was significantly higher in responders (20.1%, 11.9%, and 6.8%

in responders, partial responders, and nonresponders, respectively; $P < .001$), whereas the neutrophil percentage was significantly lower in responders before CCP therapy ($P < .01$). The level of




Figure 1. Laboratory, radiologic, and clinical changes after COVID-19 CCP therapy. (A) Proportion of patients who became virus free after 1 to 3 days, 1 to 7 days, and 1 to 14 days of CCP therapy. (B) Dynamic changes in S-, RBD-, and N-specific IgG levels before and after CCP therapy. (C-E) Dynamic changes in lymphocyte, monocyte, and neutrophil percentages before and after CCP therapy. * $P < .05$; ** $P < .01$. (F) Dynamic changes in C-reactive protein concentrations before and after CCP therapy. (G) Number and proportion of patients with radiologic improvement after 1 to 3 days, 3 to 7 days, 7 to 10 days, 10 to 14 days, and 14 to 21 days after CCP therapy. RI indicates there were radiologic improvements, and no-RI indicates that no radiologic improvements were observed after CCP therapy. (H) Proportion of patients with a SCSS that decreased within 1 week after CCP therapy. (I) Time to clinical improvement after CCP therapy in patients with different therapy timings. The x-axis represents the number of weeks from symptom onset to CCP therapy. The y-axis represents the number of days from CCP therapy to a 2-point decrease in SCSS. The number of patients at 1 to 4 weeks, 5 to 6 weeks, 7 weeks, and ≥ 8 weeks was 18, 40, 26, and 50, respectively.

C-reactive protein was significantly higher in nonresponders (5.2, 25.9, and 73.1 mg/L in responders, partial responders, and nonresponders; $P < .01$), indicating that the strong inflammatory reaction was associated with an insensitive response to CCP. In addition, the levels of lactate dehydrogenase, B-type natriuretic

peptide, urea nitrogen, procalcitonin, and glucose were markedly higher in nonresponders than in responders before CCP therapy ($P < .05$), suggesting that abnormal metabolic functions had an effect on CCP response. Although not significant, the antibody levels in CCP units, which were transfused into rapid

responders, were higher than those in moderate responders (supplemental Figure 2B). These preliminary results suggest that CCP units with high antibody levels could confer immediate immunity to recipients, and the efficacy of CCP for responders depends on the antibody levels of the donor plasma.

Patients with an SCSS of 5 before therapy showed no improvements after CCP therapy. However, within 7 days after CCP therapy, 66.7% and 83.4% of patients with an SCSS of 4 or 3, respectively, exhibited various degrees of clinical improvement (Figure 1H). This result indicates that CCP could effectively improve the respiratory symptoms of patients with severe disease and help them in being weaned from oxygen support. However, patients who were extremely critically ill could not benefit from CCP, which is consistent with the findings of studies by Li et al¹² and Liu et al,¹⁶ which showed that intubated or patients with life-threatening COVID-19 were not likely to benefit from CCP.

Experience from SARS-CoV-1 shows that convalescent plasma is most effective when administered shortly after symptom onset, typically within 2 weeks.^{7,14,17} The study by Liu et al¹⁶ showed that the effect of CCP was similar in an interval of 3 weeks' duration of symptoms. We compared the time to clinical improvement in patients with different therapy timings in our cohort, including 1 to 4 weeks, 5 to 6 weeks, 7 weeks, and ≥ 8 weeks after symptom onset. The results showed that the median time to clinical improvement was ~ 10 days in the 1 to 4 weeks', 5 to 6 weeks', and 7 weeks' groups. However, the time to clinical improvement was significantly prolonged in the ≥ 8 weeks' group (Figure 1I).

In summary, we analyzed a large cohort of patients with COVID-19 who received CCP and provide detailed evidence regarding their clinical improvement. Although the homogeneous data obtained from a single center may reduce some biases, there could inevitably be some confounding factors (eg, biased patient assignments) in this retrospective study. In addition, complete data on neutralizing antibody titers in CCP units were not available, limiting the power of evaluating the correlation between the quality of donor plasma and efficacy. Moreover, a stratified analysis of cases of severe and critical patients could not be performed due to the low proportion of critical patients. This analysis differs from existing studies in that its dynamic laboratory observations using large-scale data make it possible to analyze the potential therapeutic mechanism of CCP, recognize the characteristics of responders and nonresponders, and identify the indications and timing of therapy.¹⁸ Our results suggest that CCP, transfused even after 2 weeks (median of 45 days in our cohort) of symptom onset, could improve the symptoms and mortality in patients with severe or critical cases of COVID-19. We anticipate that this study could shed new light in clinical practice and monoclonal antibody development for COVID-19.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (grants 81572893, 81972358, and 81959113), the Key Foundation of Wuhan Huoshenshan Hospital (grant 2020[18]), the Key Research & Development Program of Jiangsu Province (grants BE2017733 and BE2018713), the Medical Innovation Project of Logistics Service (grant 18JS005), and the Basic Research Program of Jiangsu Province (grant BK20180036).

Authorship

Contribution: Q.W., C.W., and X. Xu had full access to all of the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, and were responsible for concept and design; X. Xia, Zhihua Wang, A.Z., X.L., T.L., Z.G., G.C., and Y.P. performed data collection; K.L., L.W., M.Z., B.H., J.L., Ziyu Wang, W.W., L.L., Y.C., M.W., W.L., C.L., and K.Z. contributed to data analysis and interpretation; and K.L., L.W., and B.B. drafted the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: M.Z., 0000-0003-2953-8309; B.B., 0000-0001-5007-0240; Q.W., 0000-0002-3488-1059.

Correspondence: Xiaoli Xu, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Rd, Nanjing 210002, China, e-mail: xxl2019kt@sina.com; Changjun Wang, Center for Disease Control and Prevention of PLA, 20 Dongdajie St, Beijing 100071, China, e-mail: science@hotmail.com; and Qianghu Wang, Center for Global Health, School of Public Health, Nanjing Medical University, 818 Tianyuan East Rd, Nanjing 211100, China; e-mail: wangqh@njmu.edu.cn.

Footnotes

*X. Xia, K.L., L.W., and Zhihua Wang contributed equally to this article.

For original data, please contact Qianghu Wang, wangqh@njmu.edu.cn.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

REFERENCES

- Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239.
- Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-273.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069.
- World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed 9 June 2020.
- Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends*. 2020;14(1):69-71.
- Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. *J Clin Invest*. 2020;130(4):1545-1548.
- Garraud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. *Transfus Clin Biol*. 2016; 23(1):39-44.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA*. 2020;323(16):1582.
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(17): 9490-9496.
- Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [published online ahead of print 15 April 2020]. *J Med Virol*. doi:10.1002/jmv.25882.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening

COVID-19: a randomized clinical trial [published online ahead of print 3 June 2020]. *JAMA*. doi:10.1001/jama.2020.10044.

13. Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol*. 2020;20(5):269-270.
14. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest*. 2020; 130(6):2757-2765.
15. Joyner M, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. *medRxiv*. doi:10.1101/2020.05.12.20099879.

16. Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a matched control study. *medRxiv*. doi:10.1101/2020.05.20.20102236.
17. Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):44-46.
18. Zeng F, Chen X, Deng G. Convalescent plasma for patients with COVID-19. *Proc Natl Acad Sci U S A*. 2020;117(23):12528.

DOI 10.1182/blood.2020007079

© 2020 by The American Society of Hematology

TO THE EDITOR:

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Livia Hegerova,¹ Ted A. Gooley,² Kelly A. Sweerus,³ Cynthia Maree,⁴ Neil Bailey,¹ Megumi Bailey,¹ Vanessa Dunleavy,¹ Krish Patel,¹ Kirsten Alcorn,⁵ Rebecca Haley,⁵ Jill M. Johnsen,^{5,6} Barbara A. Konkle,^{5,6} Annamarie C. Lahti,⁷ Morgan L. Alexander,⁷ Jason D. Goldman,⁴ Anne Lipke,³ Sun-jung Lim,³ Mark D. Sullivan,³ John S. Pauk,⁴ and John M. Page¹

¹Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Division of Pulmonary and Critical Care and ⁴Division of Infectious Disease, Department of Internal Medicine, Swedish Medical Center, Seattle, WA; ⁵Bloodworks Northwest, Seattle, WA; ⁶Division of Hematology, University of Washington, Seattle, WA; and ⁷Neuroscience Institute, Swedish Medical Center, Seattle, WA

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily manifests as a respiratory illness and has affected >5 million people worldwide, with >350 000 deaths.^{1,2} There are no current approved therapies for COVID-19. Administration of convalescent plasma (CP) may be effective therapy for COVID-19.³⁻⁶ Early indicators suggest that transfusion of CP is safe in COVID-19.⁷ We report the early clinical experience of 20 hospitalized patients treated with CP compared with 20 matched controls with severe or life-threatening COVID-19 infection.

Twenty patients with COVID-19 infection, diagnosed using quantitative reverse-transcriptase polymerase chain reaction assay for SARS-CoV-2 on nasopharyngeal swabs, were treated with CP in 5 hospitals in the Seattle area between April 13 and April 26 of 2020. Patients with severe or critical illness were treated with 1 unit of ABO-compatible CP under an expanded access protocol (IND 19832). Baseline demographic and clinical characteristics, including comorbidities, severity of illness, laboratory parameters, and clinical outcomes, were recorded up to 14 days after CP transfusion or the equivalent day of hospitalization for controls. Donor information was also collected. This study was approved by the Institutional Review Board of Providence St. Joseph Health.

The median age of patients treated with CP was 60 years (range, 29-95), with 20% of patients older than 80 years. The most common signs and symptoms of COVID-19 illness were cough or shortness of breath (90%), lymphopenia (67%), and an abnormal radiograph (80%). The most common comorbidities were hypertension (60%), diabetes (45%), and obesity (20%). One third of patients required mechanical ventilation (MV). Median time from hospitalization to CP was early at 2 days (interquartile range [IQR], 1-4.3). The majority of patients received additional

therapies, including azithromycin (60%), hydroxychloroquine (55%), or multiple combinations. CP recipients had primarily A (45%) or B (45%) ABO type.

The 8 COVID-19-recovered donors who provided units ranged in age from 29 to 79 years. All had symptoms of respiratory illness, muscle aches, and/or headache, but none required hospitalization. All were more >28 days past their last symptoms of COVID illness. Donations were well tolerated and without significant complications. Anti-SARS-CoV-2 immunoglobulin G serology, as determined by the Abbott ARCHITECT, was positive in all but 1 donor, whereas EuroImmun was negative (n = 1), equivocal (n = 3), moderate positive (n = 3), or high positive (n = 1).

Figure 1 shows the clinical and laboratory parameters reported over 7 days after CP. Temperature improved in all patients after delivery of CP. The mean temperature decrease was 0.3°C in the CP group (standard deviation [SD], 0.5), whereas mean absolute lymphocyte count was $1.01 \times 10^3/\mu\text{L}$ (SD, 0.47) and did not change by day 7 ($1.09 \times 10^3/\mu\text{L}$; SD, 0.55). The mean baseline C-reactive protein was 170.5 mg/L (SD, 137.6), which decreased to 127.5 mg/L (SD, 144.0) after CP. A decrease in the fraction of inspired oxygen (FiO₂) from 53% (SD, 29) to 47% (SD, 24) was seen by day 7 after CP. For patients who were on MV, the mean Pao₂/FiO₂ of inspired oxygen ratio at baseline was 81 (SD, 23), which improved to 96 (SD, 22). Two patients were liberated from the ventilator, whereas 2 required intubation after CP.

The outcomes of all patients are reported in Table 1. Median World Health Organization (WHO) ordinal scale score was 5 at CP infusion, which improved to 4.5 at day 7 and 3.5 at day 14. No adverse events with CP were reported. The incidence of venous thromboembolism (VTE) was (20%). At 7 days of follow-up, 25% of patients were discharged, whereas 10% had died.